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BACKGROUND: Type 1 hyperlipoproteinemia is a rare autosomal recessive disorder most often
caused by mutations in the lipoprotein lipase (LPL) gene resulting in severe hypertriglyceridemia
and pancreatitis.
OBJECTIVES: The aim of this study was to identify novel mutations in the LPL gene causing type 1
hyperlipoproteinemia and to understand the molecular mechanisms underlying the severe hypertrigly-
ceridemia.
METHODS: Three patients presenting classical features of type 1 hyperlipoproteinemia were
recruited for DNA sequencing of the LPL gene. Pre-heparin and post-heparin plasma of patients
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deficiency (FLD);
Hyperchylomicronemia
were used for protein detection analysis and functional test. Furthermore, in vitro experiments were
performed in HEK293 cells. Protein synthesis and secretion were analyzed in lysate and medium frac-
tion, respectively, whereas medium fraction was used for functional assay.
RESULTS: We identified two novel mutations in the LPL gene causing type 1 hyperlipoproteinemia:
a two base pair deletion (c.765_766delAG) resulting in a frameshift at position 256 of the protein
(p.G256TfsX26) and a nucleotide substitution (c.1211 T . G) resulting in a methionine to arginine
substitution (p.M404 R). LPL protein and activity were not detected in pre-heparin or post-heparin
plasma of the patient with p.G256TfsX26 mutation or in the medium of HEK293 cells over-
expressing recombinant p.G256TfsX26 LPL. A relatively small amount of LPL p.M404 R was detected
in both pre-heparin and post-heparin plasma and in the medium of the cells, whereas no LPL activity
was detected.
CONCLUSIONS: We conclude that these two novel mutations cause type 1 hyperlipoproteinemia by
inducing a loss or reduction in LPL secretion accompanied by a loss of LPL enzymatic activity.
! 2016 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Lipoprotein lipase (LPL) is an enzyme belonging to a
mammalian lipase family. Other members of this family are
pancreatic lipase, hepatic lipase, gastric lipase, and endo-
thelial lipase.1,2 The human LPL gene spans about 30 kb on
the short arm of chromosome 8 and consists of 10 exons
coding for a protein of 475 amino acids.3 Active LPL is a
noncovalent dimer with a catalytic triad consisting of three
amino acids (Ser, Asp, and His).4
LPL is a 55-KDa secreted glycoprotein synthesized from
several cell types, such as adipocytes, macrophages, and
muscle cells.5 After secretion, the protein binds to the sur-
face of capillaries through the interaction of its positively
charged heparin-binding domains6 with negatively charged
heparan sulfate proteoglycans expressed on the surface of
endothelial cells.7,8
LPL is responsible for the intravascular hydrolysis of
TG-rich lipoproteins (TG) such as chylomicrons and very
low-density lipoproteins.9,10 It catalyzes a crucial step in
the removal of TG from bloodstream generating free fatty
acids for different tissues.10 For full enzymatic activity,
LPL requires some important cofactors: (1) apolipoprotein
C-II and apolipoprotein A-V that are LPL activators; (2)
glycosylphosphatidylinositol-anchored high-density
lipoprotein-binding protein 1, which is involved in LPL
binding and transport to the endothelial cell wall; and (3)
lipase maturation factor 1 an important endoplasmic
reticulum transmembrane protein, which promotes LPL ho-
modimerization.9,11,12 Loss of function mutations in one of
all these genes result in type I hyperlipoproteinemia.13,14
Type I hyperlipoproteinemia, also known as Familial
lipoprotein lipase deficiency or Familial hyperchylomicro-
nemia, is a rare autosomal recessive disorder of lipoprotein
metabolism estimated to affect approximately one per
million individuals. In some ethnic groups, the frequency
of this disorder is several fold higher (i.e., French
Canadians, Afrikaner).15,16 Type I hyperlipoproteinemia is
characterized by extremely high levels of triglycerides in
the plasma (.880 mg/dL or 10 mmol/L) due to a massive
accumulation of chylomicrons due to impaired hydroly-
sis.17,18 Clinical features are recurrent episodes of abdom-
inal pain and pancreatitis, as well as hepatosplenomegaly,
eruptive cutaneous xanthomas, and lipemia retinalis.19
The main therapeutical approach of Type I hyper-
lipoproteinemia is based on diet treatment to reduce
triglyceride (TG) levels.20 TG-lowering drugs, such as
niacin and fibrates, are not effective in patients with type
I hyperlipoproteinemia.21 Orlistat, a gastric lipase inhibitor
that reduces fat availability, has been used successfully in
the treatment of moderate and severe LPL deficiency.22,23
Recently, gene replacement using alipogene tiparvovec
has been the very first therapy approved by European
Medicines Agency for the treatment of type I hyperlipopro-
teinemia.24 Alipogene tiparvovec introduces a human LPL
gene into the body, resulting in the production of functional
LPL.25 However, this gene therapy is indicated only in
adults with genetic diagnosis of LPL deficiency who have
had recurrent pancreatitis and with a residual lipoprotein
mass in the circulation.24,26 Thus, careful genetic screening
and functional testing of LPL are required to identify pa-
tients eligible for this new therapeutic approach.
In this article, we report two novel mutations in LPL gene
in three patients with severe hypertriglyceridemia and recur-
rent pancreatitis and show by in vitro experiments using
HEK293 cells and blood samples that these genetic muta-
tions result in different protein production and/or secretion
and in both the cases, in a nonfunctional LPL protein.
Materials and methods
Subjects
A total of three individuals were selected among
(n 5 85) referrals to the Lipid Clinic at Sahlgrenska
University Hospital in Gothenburg (Sweden), between the
first of April 2014 to the first of May 2015. Two individuals
(patients 1 and 2) belonged to the same family. All three
individuals were diagnosed with hypertriglyceridemia
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during hospitalization for the presence of pancreatitis.
Referrals were all due to the presence of hypertriglycer-
idemia defined as fasting triglycerides .6 mmol/L. Selec-
tion criteria to undergo genetic screening were fasting
triglycerides .10 mmol/L and presence of at least one
episode of pancreatitis in the absence of secondary risk
factors for hypertriglyceridemia (i.e., alcohol use, meta-
bolic syndrome, diabetes mellitus, partial lypodystrophy),
presence of consanguinity in the family. All subjects gave
informed consent to deoxyribonucleic acid (DNA) analyses
and publication.
DNA isolation and sequencing
Individual exons with flanking intron sequences of the
LPL gene were amplified from DNA extracted from
ethylenediaminetetraacetic acid-containing blood or saliva
usingDNeasyBlood kit (Qiagen,Hilden,Germany) andPure-
gene Buccal Cell Core kit (Qiagen) respectively, according to
the manufacturer’s instructions. The primers and conditions
for thermal cycling are available on request. The PCR prod-
ucts were purified using ExoSAP-IT (USB Corporation,
Cleveland, OH) according to the manufacturer’s instructions.
Version 3.1 of the BigDye terminator cycle-sequencing kit
(Applied Biosystems, Foster City, CA) was used for the
sequencing reactions according to the manufacturer’s instruc-
tions. The sequencing products were run on a Genetic
Analyzer 3730 (Applied Biosystems) and analyzed using
Secscape, version 2.5 software (Applied Biosystems).
Site-direct mutagenesis, cloning, and
transfection
Wild type LPL cDNA and c.765_766delAG LPL cDNA
were synthesized and cloned in pcDNA3.1 vector with a V5
epitope tag at the C-terminus by GeneArt Gene Synthesis
(Thermo Fisher Scientific, Rockford, IL, USA). Single
base-pair change from thymine to guanine at nucleotide
1211, resulting into a methionine to arginine substitution
(p.M404 R), was introduced by site-directed mutagenesis,
to obtain the LPL p.M404 R mutation (primer forward:
TTG GAG AAC TAC TCA GGT TGA AGC TCA AAT and
primer reverse: ATT TGA GCT TCA ACC TGA GTA GTT
CTC CAA). A detailed protocol for mutagenesis is available
on request. The presence of the LPL mutation and fidelity of
each construct were confirmed by DNA sequencing.
HEK293 cells were cultured in minimum essential media
containing 10% FBS (Fetal Bovine Serum). Expression
plasmids (30 mg/T-75 flask) containing the human wild
type LPL, c.765_766delAG LPL, or c.1211 T.G LPL, were
used to transfect HEK293 cells using TurboFect (Thermo
Fisher Scientific) reagent according to the manufacturer’s
protocol. After 48 h, cells and media were collected. Cells
were lysed in M-PER (Mammalian Protein Extraction Re-
agent, Thermo Fisher Scientific) containing complete prote-
ase inhibitor cocktail (Sigma-Aldrich, Saint Louis,
Missouri) and analyzed by western blotting. Media were
concentrated 10 times byVIVASPIN tubes (Sartorius Stedim
Biotech, Germany) and used for LPL activity measurements
and protein detection analysis by western blot analysis.
Post-heparin plasma samples
After overnight fasting, a pre-heparin blood sample was
drawn followed by an intravenously bolus injection of
heparin (60 IU/kg body weight). After 10 min, a post-
heparin blood was collected from the contralateral arm. The
blood samples were centrifuged at 3000 rpm at 4!C for
10 min to obtain pre-heparin and post-heparin plasma
samples (supernatant). The supernatants were stored at
280!C until analyzed.
LPL enzymatic activity
LPL activity in pre-heparin and post-heparin plasma
samples and in media fractions of HEK293 cells over-
expressing LPL wild type and the two mutations was
measured as previously described.27 Briefly, 7.5 mL of each
plasma sample was mixed with 42.5 mL of 0.2-M Tris HCl
buffer (pH 8.0). The diluted plasma samples and 50 mL of
each concentrated medium sample were incubated for
15 minutes at 37!C with a radiolabeled substrate
[9,10-3H(N)]-triolein (Perkin Elmer, Waltman, MA), cold
triolein, and phosphatidylcholine (Sigma-Aldrich, St Louis,
MO), heat-inactivated fetal calf serum and bovine serum al-
bumin in presence or absence of 1-M NaCl.
Lipids were extracted by the addition of heptane/
chloroform/methanol (1:1.25:1.41). Samples were centri-
fuged at 3000 g for 15 min. The amount of [3H]-oleic acid
released was measured in the upper (aqueous) phase by
scintillation counting. Mouse (C57BL/6) postheparin
plasma was used as a positive control, whereas 1-M NaCl
was used for LPL specificity.
Immunoblotting
Pre-heparin and post-heparin plasma samples were
diluted 1:50 in 0.5-M Tris-HCl (pH 7). The diluted plasma
samples, cell lysates, and concentrated media samples were
mixed with Laemmli buffer and boiled for 5 min at 95!C.
Proteins were size-separated by SDS-PAGE (10% acryl-
amide gel, 200 V, 45 min) and transferred onto a nitrocel-
lulose membrane (400 mA, 60 min). Membranes were
incubated overnight with primary antibodies, washed 2
times for 5 minutes with 0.2% tris-buffered saline Tween,
incubated 1 hour with HRP-conjugated secondary antibodies
and washed 3 times for 10 minutes with 0.2% tris-buffered
saline Tween. After 5-minute incubation with chemilumi-
nescent HRP substrate (Millipore Corporation, Billerica,
USA), bands were visualized by Chemidoc XRS System
(Biorad, Hercules, CA) and Image Lab Software (Biorad).
The following antibodies were used: mouse anti-LPL
(Sigma-Aldrich), rabbit anti-HTGL (Hepatic Triglyceride
Lipase) (Sigma-Aldrich), mouse anti-APOA1 (AbD
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Serotec, Oxford, UK), mouse anti-V5 (Invitrogen), rabbit
anti-Calnexin (Abcam), and mouse anti-Albumin (Sigma-
Aldrich).
Results
Clinical cases
A total of three individuals referred to the Lipid Clinic at
Sahlgrenska University Hospital in Gothenburg for the
presence of hyperlipidemia were screened for the presence
of mutations in the LPL gene. The criteria for genetic
screening of these patients were fasting triglycerides
.10 mmol/dL, presence of at least one episode of acute
pancreatitis requiring hospitalization and of consanguinity
in the family (see family tree in Fig. 1).
These conditions must have occurred in the absence of
present or past history of excess in alcohol consumption,
obesity, and metabolic syndrome (see Table 1 for clinical
characteristics of the patients). All probands were from
Middle East (Iran and Syria), and DNA or medical records
from family members were not available.
Figure 1 Pedigree of the families. (A) Pedigree of the family with mutation p.G256TfsX26 and (B) with mutation p.M404 R in LPL gene
displaying the structure of the second-cousin consanguineous matings. Squares and circles represent male and female family members,
respectively, and filled symbols denote affected individuals with homozygous mutations.
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Sequencing of the LPL gene
Genetic screening in the LPL gene was performed by
direct Sanger sequencing. In proband 1 and 2, we found a
two base pair deletion (c.765_766delAG; Fig. 2A) resulting
in a frame-shift leading to a premature stop codon at posi-
tion 282 (p.Gly256Thrfs*26). Both probands were homozy-
gous for this mutation. Proband 3 was homozygous for
nucleotide substitution (c.1211 T . G; Fig. 2B) resulting
into a missense mutation (methionine to arginine substitu-
tion at position 404 of the protein, p.M404 R).
LPL activity, synthesis, and secretion in
HEK293 cells
To understand the molecular mechanism underlying
hypertriglyceridemia by the novel mutations identified, we
cloned the wild type LPL cDNA and the p.G256TfsX26
mutant in a pcDNA3.1 vector and performed mutagenesis
in situ on the wild type gene to obtain the p.M404 R
mutant. A V5 tag was added at the C-terminus of the pro-
tein. Next, HEK293 cells were transiently transfected
with these constructs, and the presence of LPL was exam-
ined in the cell lysates and media (Fig. 3A and B).
HEK293 cells transfected with the mutation
p.G256TfsX26 produced about 80% less protein than
cells transfected with the wild-type LPL cDNA. The cells
transfected with the p.M404 R mutation showed virtually
no protein in the cell lysate (Fig. 3A). Consistently, in the
media, LPL was not detected for the mutation
p.G256TfsX26 and reduced by 80% for the mutation
p.M404 R (Fig. 3B).
Next, we examined LPL activity in concentrated media
from these cells overexpressing the p.G256TfsX26 and the
p.M404 R LPL mutants. No LPL activity was detected in
the media of cells transfected with either of the two mutant
plasmids (Fig. 4).
Table 1 Clinical, anthropometric, and lipoprotein profile of
the individuals screened for LPL mutations
Variable Proband 1 Proband 2 Proband 3
Age 19 32 28
Gender M F M
BMI (Kg/m2) 24.7 15.6 27.7
Alcohol intake No No No
Diabetes No No No
Triglycerides (mmol/L) 60.7 6 7 31.7 6 7.8 45 6 26.9
Pancreatitis (yes/no) Yes Yes Yes
Number of Pancreatisis 3 .10 1
Cholesterol (mmol/L) 9.3 4.1 4.1
HDL-cholesterol (mmol/L) 0.5 0.2 1
LDL-cholesterol (mmol/L) 0.7 0.24 0.6
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.
Figure 2 Sequence analysis of the LPL mutations. (A) Segments of genomic DNA sequences of the proband 1 and 2 showing nucleotides
c.765_766, which are deleted on both alleles in the affected subjects; deleted nucleotides are shown in the red box in the sequence from the
control subject. (B) Segments of genomic DNA sequences of the proband 3 showing mutated nucleotide c.1211 T . G in the red box.
(Color version of figure is available online.)
820 Journal of Clinical Lipidology, Vol 10, No 4, August 2016
LPL activity and circulating LPL levels
Pre-heparin and post-heparin plasma samples were
collected from patients homozygous for the p.G256TfsX26
or the p.M404 R for LPL activity measurement. In the post-
heparin plasma of the p.G256TfsX26 homozygotes, no
release of oleic acid from triolein was observed indicating
noLPL activity (Fig. 5). In the post-heparin plasma of the sub-
ject homozygous for the p.M404 R mutation, a fairly small
amount of oleic acid releasewas detected (Fig. 5). This release
was not inhibited by sodium chloride suggesting that it was
due toHTGL.As no lipase activitywas detected in the plasma
of patients, we examined protein levels in the serum.
LPLproteinwas absent in the pre-heparin and post-heparin
plasma of the subject homozygous for the p.G256TfsX26
(Fig. 6A), whereas it was present at a very low level in the
pre-heparin and post-heparin plasma of the p.M404 R
Figure 3 In HEK293 cells transiently transfected,
p.G256TfsX26 LPL mutation is less produced and not secreted,
whereas p.M404 R LPL is less produced and secreted. (A) West-
ern blotting showing levels of LPL-V5 tagged in the cell lysates of
HEK293 cells transfected with wild type, p.G256TfsX26, and
p.M404 R LPL; calnexin was used as loading control. (B) Western
blotting showing levels of LPL-V5 tagged in the cell media of
HEK293 cells transfected with wild type, p.G256TfsX26, and
p.M404 R LPL; albumin was used as loading control.
Figure 4 LPL activity is absent in the cell media of
HEK293 cells transfected with p.G256TfsX26 and p.M404 R
LPL. LPL induced release of radiolabeled oleic acid from triolein
was measured in cell media of HEK293 transiently transfected
with wild type, p.G256TfsX26, and p.M404 R LPL. Wild type
LPL medium was used as a positive control. Sodium chloride
1 M (NaCl) was used to inhibit specifically LPL activity.
Figure 5 LPL activity is absent in pre-heparin and post-heparin
plasma from individuals with p.G256TfsX26 or p.M404 R muta-
tions. LPL induced release of radiolabeled oleic acid from triolein
was measured in pre-heparin and post-heparin plasma from sub-
jects homozygous for the two base pair deletion frameshift muta-
tion (p.G256TfsX26) and the missense mutation (p.M404 R).
Mouse post-heparin plasma was used as a positive control for
increased LPL activity in post-heparin plasma. Sodium chloride
1 M (NaCl) was used to inhibit specifically LPL activity. Pre-h:
pre-heparin; Post-h: post-heparin; NaCl: sodium chloride.
Figure 6 Circulating LPL levels in pre-heparin and post-heparin
plasma from subjects with p.G256TfsX26 or p.M404 R mutation.
(A) Western blotting showing circulating levels of LPL and HTGL
in pre-heparin and post-heparin plasma samples from a subject
carrying the p.G256TfsX26 mutation and (B) the p.M404 R muta-
tion. Mouse post-heparin plasma was used as a positive control
(mouse and human LPL amino acidic sequences show .90%
homology). Anti-human APOA1 antibody was used as a loading
control. Pre-h, preheparin; Post-h, postheparin; KDa, kilodalton;
LPL, lipoprotein lipase; HTGL, hepatic triglyceride lipase;
APOA1, apolipoprotein A1.
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homozygotes (Fig. 6B). HTGL was present at low level in
both individuals in the pre-heparin and increased in the
post-heparin plasma of both patients.
Discussion
Type I hyperlipoproteinemia is a rare autosomal reces-
sive disorder of lipoprotein metabolism caused by muta-
tions in the LPL gene.19,28 In this study, we have identified
two novel mutations in the LPL gene causing type I
hyperlipoproteinemia.
In our genetic screening, we obtained a high success rate
in detecting mutation in the LPL gene. This may be due to
the stringent criteria that we used to identify probands.
Indeed the inclusion of only individuals with the presence
of at least one pancreatitis episode in the absence of meta-
bolic and alcohol-related cause of hypertriglyceridemia
restricted the number of individuals screened. It is also
worth noting that all three of our probands had a consan-
guineous marriage explaining the presence of the disease
in a homozygous state.
Gothenburg area has approximately 600,000 inhabitants.
The prevalence of LPL deficiency is estimated to be one in
one million. Since the early 1970s, Sweden has had a large
migratory flux from Middle East,29 the region where the
three probands came from. In this region, consanguineous
marriage is relatively common.30 We identified two muta-
tions (p.G256TfsX26 and the p.M404 R) that to the best
of our knowledge have not been previously reported. These
mutations are not annotated in the Exome Aggregate Con-
sortium (ExAC) database, which comprises more than
60,000 individuals. To date, more than 220 pathogenic mu-
tations have been identified (70% missense, 10% nonsense,
18% rearrangements, and 2% unknown mutations).31,32 In
silico analysis using PolyPhen2 and SIFT prediction pro-
grams indicated that mutation M404 R was probably
damaging.
To understand the molecular mechanism underlying our
genetic findings, we showed that HEK293 cells transfected
with a plasmid encoding the mutation p.G256TfsX26
produced about 80% less protein than cells transfected
with the wild type LPL, whereas the cells transfected with
the p.M404 R mutation showed even much lower abun-
dance of the protein. In the media of the transfected cells,
the LPL protein was not detected for the mutation
p.G256TfsX26 and reduced by 80% for the mutation
p.M404 R. No LPL activity was detected in concentrated
media from these cells transfected with both the mutations.
Consistently, no lipase activity was detected in the pre-hep-
arin or post-heparin plasma of patients, and LPL was absent
from post-heparin plasma of the p.G256TfsX26 homozy-
gote but was present at a very low level in the pre-heparin
and post-heparin plasma of the p.M404 R homozygotes.
Taken together, these data suggest that both the mutations
severely affect the protein synthesis/secretion and conse-
quently the enzymatic activity of LPL protein, explaining
the severe phenotype in the patients carrying these
mutations.
In particular, we speculate that the LPL p.G256TfsX26
causes mRNA decay.33
Regarding the p.M404 R mutation, LPL acts as a
homodimeric enzyme, and each monomer consisting of a
larger N-terminal catalytic domain and a smaller C-termi-
nal region that plays a key role in binding triglyceride
substrates.34–37 In 2011, Voss et al. have shown that LPL’s
C terminus plays an important role in LPL–GPIHBP1 inter-
actions. In fact, a pair of missense mutations in LPL’s
C-terminal domain, p.C418Y and p.E421 K, abolishes
LPL’s capacity to bind to GPIHBP1.38 This finding could
explain why the administration of heparin did not change
levels of the LPL in proband 3. Furthermore, other two mu-
tations in the LPL’s C-terminal, the E410 V and G412 R
mutation, were associated with very low levels of LPL
mass and activity in the post-heparin plasma.39,40 However,
the mechanism on the basis of these effects is not clear, and
we hypothesize that LPL p.M404 R is degraded within
cells. Moreover, in our in vitro experiments, we show no
LPL activity despite residual secretion indicating a loss of
the enzymatic activity in this mutant.
In conclusion, we have described two novel mutations of
the LPL gene causing Type I hyperlipoproteinemia by dis-
rupting LPL synthesis and enzymatic activity.
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